ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2604

Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis

Caroline Evers 1, Suzana Jordan 1, Britta Maurer 1, Rucsandra Dobrota 1, Petra Hoederath 2 and Oliver Distler3, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Centre for Neurosurgery, Hirslanden, St. Gallen, St. Gallen, Switzerland, 3Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Chronic pain and low back pain, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Pain is a frequent, yet inadequately explored challenge in patients with systemic sclerosis (SSc). The aim of this study was to conduct an extensive pain assessment, examining pain chronification and its association with disease manifestation.

Methods: Consecutive SSc patients attending their annual assessment in the Department of Rheumatology, Zurich, Switzerland were included into the study. SSc specific features were addressed as defined by European Scleroderma Trial and Research Group (EUSTAR). We conducted a detailed pain analysis including pain intensity, localization, treatment, pain chronification grade according to the Mainz Pain Staging System (MPSS), general well-being using the Marburg questionnaire on habitual health findings (MFHW), as well as symptoms of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS).

Results: One hundred forty seven SSc patients completed a pain questionnaire, 118/147 (80.3%) reported pain and were included for further assessment. The median pain intensity during the last 4 weeks was 4/10 on a numeric rating scale (NRS). The most frequent major pain localizations were hand and lower back. The number of patients with low back pain as main pain was significantly higher in patients with very early SSc than in patients with advanced and established disease stages (p = 0.01). Those patients also showed the highest amount of pathological HADS scores for depression as well as for anxiety with 25% each and more pathological scores in the MFHW. Regarding pain chronification, 34.8% of all patients were in stage I according to the Mainz Pain Staging System, 45.2% in stage II and 20.0% in stage III. There was no significant correlation with chronification grade and disease severity, but higher chronification grades were significantly more frequent in patients with low back pain (p = 0.024). Advanced chronification was also significantly associated with pathological scores in the HADS (p < 0.0001) and was linked with decreased well-being. Therefore, patients with primarily back pain showed more pathological HADS scores than those with primarily hand pain. Patients with higher chronification grades also showed more pain related effects like higher use of analgesics and poorer subjective therapy effects. Furthermore, we found that most patients did not receive adequate pain therapy; only 4.4% of all examined patients reported seeing a pain specialist.

Conclusion: Contrary to our expectations, pain severity and chronification were not associated with more severe disease manifestation in systemic sclerosis. This study showed that low back pain, being associated with advanced pain chronification and increasing psychological problems, represents an important problem in patients with systemic sclerosis, especially in early stages of the disease. Therefore, our study implies that also non-disease specific symptoms such as low back pain need to be considered in SSc patients and it underlines the importance of preventing pain chronification in order to enhance quality of life for these patients.


Disclosure: C. Evers, None; S. Jordan, None; B. Maurer, None; R. Dobrota, None; P. Hoederath, None; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5.

To cite this abstract in AMA style:

Evers C, Jordan S, Maurer B, Dobrota R, Hoederath P, Distler O. Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pain-chronification-and-the-important-role-of-non-disease-specific-symptoms-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pain-chronification-and-the-important-role-of-non-disease-specific-symptoms-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology